Literature DB >> 17478620

Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003.

Amy L Olson1, Jeffrey J Swigris, Dennis C Lezotte, Jill M Norris, Carla G Wilson, Kevin K Brown.   

Abstract

RATIONALE: From the late 1970s to the early 1990s, studies found that mortality rates for pulmonary fibrosis were increasing. Recent data for mortality from pulmonary fibrosis are unavailable.
OBJECTIVES: We sought to determine mortality rates for pulmonary fibrosis in the United States from 1992 through 2003.
METHODS: Using data from the National Center for Health Statistics, we calculated age-adjusted mortality rates from the deaths of persons with pulmonary fibrosis and stratified the data to determine differences in mortality rates by age, sex, race/ethnicity, and geography of the decedent. We developed a multivariable model to predict future mortality rates, and we determined the underlying cause of death in patients with pulmonary fibrosis.
MEASUREMENTS AND MAIN RESULTS: From 1992 to 2003, there were 28,176,224 deaths in the United States and 175,088 decedents with pulmonary fibrosis. The average age- and sex-adjusted mortality rate was 50.8 per 1,000,000 people. The age-adjusted mortality rate increased 28.4% in men (from 40.2 deaths per 1,000,000 in 1992 to 61.9 deaths per 1,000,000 in 2003) and 41.3% in women (from 39.0 deaths per 1,000,000 in 1992 to 55.1 deaths per 1,000,000 in 2003). While increases were significant in both men and women (p < 0.0001), the rate of increase was higher in women (p < 0.0001). The most common cause of death in patients with pulmonary fibrosis was the disease itself.
CONCLUSIONS: From 1992 to 2003, mortality rates for pulmonary fibrosis significantly increased. Further investigation is needed to determine the etiology of these trends, which are predicted to continue to increase.

Entities:  

Mesh:

Year:  2007        PMID: 17478620     DOI: 10.1164/rccm.200701-044OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  163 in total

Review 1.  Genetic interstitial lung disease.

Authors:  Megan Stuebner Devine; Christine Kim Garcia
Journal:  Clin Chest Med       Date:  2011-12-06       Impact factor: 2.878

2.  Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop.

Authors:  Tracy A Lieu; David Au; Jerry A Krishnan; Marc Moss; Harry Selker; Andrea Harabin; Virginia Taggart; Alfred Connors
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

3.  Altered DNA methylation profile in idiopathic pulmonary fibrosis.

Authors:  Yan Y Sanders; Namasivayam Ambalavanan; Brian Halloran; Xiangyu Zhang; Hui Liu; David K Crossman; Molly Bray; Kui Zhang; Victor J Thannickal; James S Hagood
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

Review 4.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

5.  Gender influences the response to experimental silica-induced lung fibrosis in mice.

Authors:  David M Brass; Sean P McGee; Mary K Dunkel; Sarah M Reilly; Jacob M Tobolewski; Tara Sabo-Attwood; Cheryl L Fattman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

6.  Regulation of Collagen V Expression and Epithelial-Mesenchymal Transition by miR-185 and miR-186 during Idiopathic Pulmonary Fibrosis.

Authors:  Guang-Sheng Lei; Hannah L Kline; Chao-Hung Lee; David S Wilkes; Chen Zhang
Journal:  Am J Pathol       Date:  2016-07-05       Impact factor: 4.307

7.  8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study.

Authors:  Baruch Vainshelboim; Mordechai Reuven Kramer; Jonathan Myers; Avraham Unterman; Shimon Izhakian; Jose Oliveira
Journal:  Lung       Date:  2019-01-02       Impact factor: 2.584

Review 8.  It's all about sex: gender, lung development and lung disease.

Authors:  Michelle A Carey; Jeffrey W Card; James W Voltz; Samuel J Arbes; Dori R Germolec; Kenneth S Korach; Darryl C Zeldin
Journal:  Trends Endocrinol Metab       Date:  2007-08-30       Impact factor: 12.015

9.  Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin.

Authors:  Jacob Kach; Nathan Sandbo; Nan Sethakorn; Jesse Williams; Eleanor B Reed; Jennifer La; Xinyong Tian; Susan D Brain; Kavitha Rajendran; Ramaswamy Krishnan; Anne I Sperling; Konstantin Birukov; Nickolai O Dulin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-12       Impact factor: 5.464

10.  [Pulmonary fibrosis].

Authors:  A Prasse; J U Holle; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.